Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017, Children's Hospital Boston
In type 1 diabetes, autoreactive T-cells attack insulin-producing islet cells in the pancreas (frame 1). Fiorina and colleagues showed that the network of genetic regulatory factors controlling production of a protein called PD-L1 is altered in blood stem cells from diabetic mice and humans. They then showed that PD-L1 production could be stimulated by treating blood stem cells with gene therapy or with small molecules (frame 2). The treated stem cells, now bearing PD-L1, home to the pancreas (frame 3), where they bind to the autoreactive T-cells, rendering them harmless (frame 4). In a mouse model, this reverses type 1 diabetes. Credit: Andrea Panigada/Nancy Fliesler

Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) with type 1 diabetes. The cells curbed the autoimmune reaction in cells from both mice and humans and reversed hyperglycemia in diabetic mice.

Findings were published today in Science Translational Medicine. "There's really a reshaping of the immune system when you inject these cells," says Paolo Fiorina, MD, PhD, of Boston Children's, senior investigator on the study.

The study shows that the treated stem cells, given to , home to the pancreas where islet cells are made. Almost all the mice were cured of in the short term, and one third maintained normal for the duration of their lives. The treatment was effective whether PD-L1 production was stimulated through gene therapy or pre-treatment with .

The powers of PD-L1

Previous studies have tried using immunotherapies for type 1 diabetes, aiming to curb the autoimmune attack on the body's . These attempts have failed, in part because the therapies have not targeted diabetes specifically. Autologous bone-marrow transplant—infusing patients with their own stem cells to reboot their immune system—has helped some patients, but not all.

Animation illustrating a new cell-based therapy for type 1 diabetes. Credit: Andrea Panigada

"Blood stem cells have immune-regulatory abilities, but it appears that in mice and humans with diabetes, these abilities are impaired," says Fiorina, in Boston Children's Division of Nephrology. "We found that in diabetes, blood stem cells are defective, promoting inflammation and possibly leading to the onset of disease."

A team led by Fiorina and first author Moufida Ben Nasr, PhD, also of Boston Children's, began by profiling the transcriptome of blood stem cells to find out what proteins the cells are making.

Using a gene expression microarray, they found that the network of genetic regulatory factors (microRNAs) controlling production of PD-L1 is altered in blood stem cells from and humans. This prevents production of PD-L1, even early in the disease.

They further showed that PD-L1 has a potent anti-inflammatory effect in the context of type 1 diabetes.

PD-L1 is known as an immune "checkpoint" molecule. It binds to the PD-1 receptor (inhibitory programmed death 1) on the inflammatory T-cells that are activated to cause autoimmune reactions. This causes the T-cells to die or become anergic (or inactive).

Scientists reverse diabetes in a mouse model using modified blood stem cells
Microscopic image of a mouse pancreas showing the immune checkpoint molecule PD-L1 in green. Credit: M. Ben Nasr et al., Science Translational Medicine (2017)

When Fiorina, Ben Nasr and colleagues introduced a healthy gene for PD-L1 into the stem cells, using a harmless virus as the carrier, the treated cells reversed diabetes in the mice. Fiorina and colleagues also found they could achieve the same effect by treating the cells with a "cocktail" of three small molecules: interferon beta, interferon gamma and polyinosinic-polycytidylic acid.

"We think resolution of PD-L1 deficiency may provide a novel therapeutic tool for the disease," Ben Nasr says.

Future directions

Further study will be needed to determine how long the effects of the cell therapy last and how often the treatment would need to be given. "The beauty of this approach is the virtual lack of any adverse effects, since it would use the patients' own ," says Fiorina.

In collaboration with scientists from Fate Therapeutics (San Diego, Calif.), Fiorina and colleagues are working to optimize the small-molecule "cocktail" used to modulate the . The team has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration to support the conduct of a clinical trial in type 1 diabetes.

Explore further: 'Educating' patients' immune cells may help combat diabetes

More information: M. Ben Nasr el al., "PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aam7543

Related Stories

'Educating' patients' immune cells may help combat diabetes

July 7, 2017
New research reveals that a treatment called Stem Cell Educator therapy is safe and effective for treating type 1 and type 2 diabetes. The therapy cultures the patient's immune cells with cord blood stem cells and returns ...

Rescuing intestinal stem cells from attack in type 1 diabetes

October 1, 2015
Up to 80 percent of people with long-standing type 1 diabetes develop gastrointestinal symptoms—abdominal pain, bloating, nausea, vomiting, diarrhea, constipation and fecal incontinence—that severely diminish quality ...

Autoimmune drug may help prevent kidney disease caused by diabetes

March 27, 2014
A drug currently used to treat autoimmune disease may also help prevent the kidney-damaging effects of diabetes, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). ...

Preclinical drug developed to prevent gastrointestinal side effects of type 1 diabetes

October 1, 2015
Up to 80% of individuals living with long-term type 1 diabetes experience gastrointestinal symptoms such as abdominal distension, irritable bowel syndrome, and fecal incontinence. A study publishing October 1 in Cell Stem ...

Could modifying gut microbes prevent or delay type 1 diabetes?

September 12, 2017
Autoimmune diseases such as type 1 diabetes are controlled by our genes. While researchers are eager to find out what other factors could contribute to this disease, a new study published by Yale researchers provides direct ...

Scientists use uterine stem cells to treat diabetes

September 14, 2011
Controlling diabetes may someday involve mining stem cells from the lining of the uterus, Yale School of Medicine researchers report in a new study published in the journal Molecular Therapy. The team treated diabetes in ...

Recommended for you

Diagnosing diabetes from a single blood sample

June 18, 2018
Diagnosing type 2 diabetes in clinical practice may require only a single blood sample, according to a study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Lentils significantly reduce blood glucose levels, study reveals

June 13, 2018
Replacing potatoes or rice with pulses can lower your blood glucose levels by more than 20 per cent, according to a first-ever University of Guelph study.

Is there a link between diabetes and Parkinson's disease?

June 13, 2018
People with type 2 diabetes may have an increased risk of having a diagnosis of Parkinson's disease later in life, according to a large study published in the June 13, 2018, online issue of Neurology, the medical journal ...

Double-checking diabetes medications may reduce re-hospitalizations

June 11, 2018
Clinicians may take upwards of 15 minutes to double-check a patient's medication list in an electronic health record system, but according to a new study, this reconciliation process may be well worth the time for diabetes ...

How a gene linked to obesity could provide new insights into diabetes

June 8, 2018
A gene previously linked with obesity has been found to affect how the body processes insulin, with potential implications for some forms of diabetes.

New hope from the 'seven year switch' in type 1 diabetes

June 8, 2018
New research has shown that the rapid decline in insulin production that causes Type 1 diabetes continues to fall over seven years and then stabilises.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.